MiNK Therapeutics (INKT) announced the appointment of Colonel Ret. John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
- Mink Therapeutics’ Earnings Call: Clinical Progress Amid Financial Challenges
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating
- MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright